Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
humanized GPC1-ADC (MMAE)
- Development stage
- Preclinical
- Lead developer
- Kochi University
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Humanized GPC1-ADC (MMAE)** is an academic, preclinical glypican-1-targeted antibody-drug conjugate composed of the humanized anti-GPC1 monoclonal antibody clone T2 conjugated to monomethyl auristatin E through maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl cleavable linkers. It binds cell-surface glypican-1, is internalized by GPC1-positive tumor cells, and releases MMAE intracellularly, causing microtubule disruption, G2/M-phase arrest, and apoptosis. The vc-PABC linker and membrane-permeable MMAE payload also support bystander killing of adjacent GPC1-negative tumor cells. The construct has shown preclinical activity in GPC1-positive pancreatic ductal adenocarcinoma, esophageal squamous cell carcinoma, glioblastoma, gastric cancer, and lung squamous cell carcinoma models; no INN, commercial brand, clinical trial program, regulatory approval, or commercial manufacturer has been identified. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S1476558621000610))
- Other names
- humanized GPC1-ADC(MMAE)
02
Targets
GPC1 (Glypican-1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on humanized GPC1-ADC (MMAE).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on humanized GPC1-ADC (MMAE).